CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cullinan Management (CGEM – Research ...

New Stocks Added to the Biotech Directories : Camp4 Therapeutics Corp (Nasdaq:CAMP ) is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein ...

About CAMP4 Therapeutics Corporation CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits.

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.

New Stocks Added to the Biotech Directories: Camp4 Therapeutics Corp (Nasdaq:CAMP) is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein ...

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report released on Monday. The brokerage set a “hold” rating on the stock.

In a report released today, Reni Benjamin from JMP Securities maintained a Hold rating on Allogene Therapeutics (ALLO – Research Report). The company’s shares closed last Friday at $3.08.

Century Therapeutics, Inc. (IPSC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Atossa Therapeutics focuses on developing endoxifen for hormone receptor-positive breast cancer, with promising early-stage trial results but lacks definitive proof of efficacy. The company has ...